Integra Therapeutics, a biotechnology company specialising in next-generation genome editing technology and a member of Catalonia.health, has announced the appointment of Miles Gerson as Independent Chair of its Board of Directors. The appointment strengthens the company’s corporate governance and supports its growth strategy and the development of advanced therapies.
Miles Gerson brings more than 20 years of experience in healthcare investment, business development, licensing, technology transfer and company creation. Throughout his professional career, he has also been involved in the founding leadership of early-stage companies and has held various senior operational roles in biomedical companies in the United States and Europe.
The appointment comes at a key moment for Integra Therapeutics, which recently published an article in Nature Biotechnology demonstrating the use of artificial intelligence not only to optimise enzymatic activity but also to design new synthetic proteins capable of editing the human genome more efficiently.
Avencia Sanchez-Mejias, PhD, CEO and co-founder of Integra Therapeutics, said: “We are delighted to welcome Miles as Chair of the Board of Directors. His deep industry knowledge, strategic vision and proven track record in supporting high-growth healthcare companies will be of great value in driving the company’s next phase of growth, strategically aligning our platform, pipeline and global expansion.”
Miles Gerson added: “It is an honour to take on the role of Independent Chair of Integra Therapeutics and to be part of a growing company committed to transforming advanced therapies. Integra’s core methodology, based on artificial intelligence trained on proprietary biological datasets and refined through empirical validation, clearly differentiates the company and positions it to advance towards high-impact in vivo applications, including next-generation CAR-T therapies, while addressing the key challenges of the next wave of advanced therapies.”
Comments